KRAS and neoplasm: Thus, despite the large difference in the ability of KRAS G12C and KRAS G12D to drive tumor growth, as well as their known biochemical differences34, lung tumor growth driven by these oncogenic variants was similarly affected by alterations in oncogene-proximal tumor suppressors.